MAX
Company Analysis Oruka Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (263.13%) is higher than the sector average (0.14%).
- Current debt level 0% is below 100% and has decreased over 5 years from 0.89%.
Disadvantages
- Price (34.12 $) is higher than fair price (23.66 $)
- Dividends (0%) are below the sector average (0%).
- The company's current efficiency (ROE=0%) is lower than the sector average (ROE=253.66%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Oruka Therapeutics, Inc. | Index | ||
|---|---|---|---|
| 7 days | 2.5% | 1.8% | 0.2% |
| 90 days | 15.8% | -1.3% | -0.9% |
| 1 year | 263.1% | 0.1% | 17.7% |
ORKA vs Sector: Oruka Therapeutics, Inc. has outperformed the "" sector by 262.99% over the past year.
ORKA vs Market: Oruka Therapeutics, Inc. has outperformed the market by 245.44% over the past year.
Stable price: ORKA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ORKA with weekly volatility of 5.06% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (34.12 $) is higher than the fair price (23.66 $).
Price is higher than fair: The current price (34.12 $) is 30.7% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (0) is higher than that of the sector as a whole (-335.61).
P/E vs Market: The company's P/E (0) is higher than that of the market as a whole (-104.3).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0) is higher than that of the sector as a whole (-1320.1).
P/BV vs Market: The company's P/BV (0) is lower than that of the market as a whole (72.17).
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (28.76).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (114).
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is higher than that of the sector as a whole (-870.14).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is higher than that of the market as a whole (-78.04).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-20%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-46.03%).
6.4. ROE
ROE vs Sector: The company's ROE (0%) is lower than that of the sector as a whole (253.66%).
ROE vs Market: The company's ROE (0%) is higher than that of the market as a whole (-6.22%).
6.6. ROA
ROA vs Sector: The company's ROA (0%) is higher than that of the sector as a whole (-37.56%).
ROA vs Market: The company's ROA (0%) is lower than that of the market as a whole (38.45%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.79%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
